Pre-RAI Monocyte-to-Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate-Risk DTC, While PNI and NRI Show No Prognostic Value.

Key Points

• To determine the prognostic value of pre-RAI monocyte-to-lymphocyte ratio in predicting recurrence risk in intermediate-risk DTC.
• Analyzed pre-RAI monocyte-to-lymphocyte ratio from patient samples.
• Evaluated its association with recurrence risk in intermediate-risk differentiated thyroid cancer.
• Compared findings with prognostic values of PNI and NRI.
• Identified pre-RAI monocyte-to-lymphocyte ratio as a significant predictor of recurrence risk.
• Found that PNI and NRI did not show reliable prognostic value for recurrence.
• Indicated that higher pre-RAI MLR correlates with increased recurrence risk in intermediate-risk DTC.